Panbela Therapeutics, Inc. PBLA OTC

Other OTC • Healthcare • Biotechnology • US • USD

Panbela Therapeutics, Inc. (PBLA) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 2 Buy, 1 Hold.

PBLA Analyst Ratings

Buy

Ratings

2 Buy

1 Hold

Based on 3 analysts giving stock ratings to Panbela Therapeutics, Inc. in the past 3 months

Rating breakdown

Buy

2 67%

Hold

1 33%

67%

Buy

2 analysts

33%

Hold

1 analysts

Sell

0 analysts

People Also View

Unicycive Therapeutics, Inc.

$6.97

+0.43%

KPRX

Kiora Pharmaceuticals, Inc.

$2.54

+4.10%

SONN

Sonnet BioTherapeutics Holdings, Inc.

$1.26

-59.35%

REVB

Revelation Biosciences, Inc.

$1.26

+5.00%

HILS

Hillstream BioPharma, Inc.

$0.24

+5.66%

QNRX

Quoin Pharmaceuticals, Ltd.

$6.49

+3.02%

CDIO

Cardio Diagnostics Holdings, Inc.

$2.01

+4.69%

Panbela Therapeutics, Inc. PBLA OTC

PBLA Analyst Ratings

People Also View

Get Undervalued Stock Alerts